CRDF Cardiff Oncology Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CRDF

Price (delayed)

$1.31

Market cap

$101.91M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.6

Enterprise value

$93.17M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 31

Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, ...

Highlights
Cardiff Oncology's debt has shrunk by 61% YoY and by 29% QoQ
Cardiff Oncology's EPS has increased by 31% YoY and by 10% QoQ
The equity has dropped by 55% year-on-year and by 24% since the previous quarter
The quick ratio has contracted by 25% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.cardiffoncology.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of CRDF

CRDF stock price

How has the Cardiff Oncology stock price performed over time
Intraday
-1.5%
1 week
-2.96%
1 month
48.85%
1 year
-35.78%
YTD
-53.38%
QTD
0.77%

Financial performance

How have Cardiff Oncology's revenue and profit performed over time
Revenue
$508,000
Gross profit
$508,000
Operating income
-$42.27M
Net income
-$40.05M
Gross margin
100%
Net margin
-7,884.1%
CRDF's operating income is up by 22% year-on-year and by 11% since the previous quarter
The net income has increased by 21% year-on-year and by 11% since the previous quarter
Cardiff Oncology's net margin has increased by 16% YoY and by 8% QoQ
The operating margin rose by 16% year-on-year and by 8% since the previous quarter

Price vs fundamentals

How does CRDF's price correlate with its fundamentals

Growth

What is Cardiff Oncology's growth rate over time

Valuation

What is Cardiff Oncology stock price valuation
P/E
N/A
P/B
3.38
P/S
176.38
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
183.41
Cardiff Oncology's EPS has increased by 31% YoY and by 10% QoQ
The stock's price to book (P/B) is 72% more than its 5-year quarterly average of 2.0
The equity has dropped by 55% year-on-year and by 24% since the previous quarter
The P/S is 37% less than the 5-year quarterly average of 282.5 and 27% less than the last 4 quarters average of 244.4
Cardiff Oncology's revenue has decreased by 7% YoY and by 3.2% from the previous quarter

Efficiency

How efficient is Cardiff Oncology business performance
Cardiff Oncology's return on equity has decreased by 32% YoY and by 8% QoQ
CRDF's return on assets is down by 19% year-on-year and by 6% since the previous quarter
The company's return on invested capital fell by 18% YoY and by 15% QoQ
Cardiff Oncology's return on sales has increased by 16% YoY and by 8% QoQ

Dividends

What is CRDF's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRDF.

Financial health

How did Cardiff Oncology financials performed over time
Cardiff Oncology's total assets has shrunk by 51% YoY and by 24% QoQ
The total liabilities has declined by 37% year-on-year and by 25% since the previous quarter
Cardiff Oncology's debt is 98% lower than its equity
Cardiff Oncology's debt has shrunk by 61% YoY and by 29% QoQ
The equity has dropped by 55% year-on-year and by 24% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.